Novartis signs drug delivery deal with Alteogen worth up to $3.22B
NVS Novartis AG ADR
$162.46 +0.75%
View chart & analysis → - 1Novartis (NVS) signs drug delivery deal with Alteogen to convert intravenous biologics to subcutaneous injections
- 2Based on Alteogen's Hybrozyme platform and ALT-B4 enzyme; the up to $3.22B is mostly milestone-based and conditional
- 3Goal: shorten infusion times and improve treatment convenience to counter more convenient competing formulations
This 3-line summary is compiled from the report below.
GuruFocus.com +2 View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.